Efficacy and Safety of endTB Regimens for Fluoroquinolone-Susceptible RR-TB in People With HIV
Background: endTB (NCT02754765) was an open-label Phase 3 randomized, controlled clinical trial to evaluate the efficacy and safety of five 9-month, all-oral regimens for fluoroquinolone-susceptible rifampin-resistant TB, compared to the WHO-recommended standard of care, in people 15 years of age or older. In the primary analysis, three experimental regimens (9BLMZ, 9BCLLfxZ, and 9BDLLfxZ) had noninferior…